Drug Trial Radar · NCT07697157
The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Mar 1, 2025
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary objective: 1. To evaluate the effect of Itraconazole ( CYP3A and P-gp inhibitors) on HMPL-453 pharmacokinetics(PK) in healthy subjects 2. To evaluate the effect of Rifampin (CYP enzyme inducer) on HMPL-453 pharmacokinetics (PK) in healthy subjects Secondary objectives: To evaluate the safety of HMPL-453 with and without itraconazole or rifampin following a low-fat meal in healthy subjects Exploratory objectives: 1. Assess cholesterol and 4β- hydroxycholesterol in plasma CYP3A4 Biomarker Concentration Levels ; 2. Explore proarrhythmic effect of HMPL-453 \[Results of exploratory objectives analyses will be reported separately and not included in the clinical trial Study Report (CSR)\]
Conditions
- Health, Subjective
Interventions
HMPL-453 with ItraconazoleDrug
HMPL-453: 100mg, D1、D14; Itraconazole: 400mg, D10;200mg,D11-D22
HMPL-453 with RifampinDrug
HMPL-453: 300mg, D1、D16; Rifampin: 600mg, D10-D24
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC 0-tTime frame: 25Days
- AUC 0- ∞Time frame: 25Days
- C maxTime frame: 25Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
yijishan Hospital
Wuhu, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.